10-Q: Allogene Q3 2025: Clinical Progress, Financial Headwinds

Allogene Therapeutics reports reduced net losses and significant clinical advancements for its CAR T programs, while managing a workforce reduction and ongoing capital needs.

Summary

• Allogene Therapeutics, a clinical-stage immuno-oncology company, reported a net loss of $41.4 million for the three months ended September 30, 2025, a decrease from $66.293 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $152.1 million, down from $197.7 million in the prior year period.
• The company's accumulated deficit reached $2.0 billion as of September 30, 2025.
• Cash, cash equivalents, and investments totaled $277.1 million as of September 30, 2025, with a projected cash runway into the second half of 2027.
• Research and development expenses decreased to $31.2 million for the three months and $121.5 million for the nine months ended September 30, 2025, compared to $44.7 million and $147.3 million, respectively, in 2024.
• General and administrative expenses also decreased to $13.7 million for the three months and $43.0 million for the nine months ended September 30, 2025, from $16.3 million and $49.7 million, respectively, in 2024.
• A workforce reduction of approximately 28% of employees was initiated in May 2025, resulting in $3.3 million in cash-based severance expenses and $1.3 million in equipment impairment charges.
• The ALPHA3 pivotal Phase 2 clinical trial for cema-cel in large B-cell lymphoma (LBCL) patients is progressing, with the lymphodepletion regimen standardized to fludarabine and cyclophosphamide (FC) after the FCA arm was closed due to a Grade 5 adverse event attributed to ALLO-647.
• ALLO-316 for renal cell carcinoma (RCC) received Regenerative Medicine Advanced Therapy (RMAT) designation and showed a 31% confirmed overall response rate in patients with high CD70 expression in Phase 1b data.
• ALLO-329 for autoimmune diseases (AID) received three Fast Track Designations and initiated a Phase 1 rheumatology basket study in Q2 2025, with proof-of-concept data expected by H1 2026.

Sentiment

Score: 6

Explanation: The company shows positive momentum in clinical development and reduced financial losses, extending its cash runway. However, significant risks remain, including the need for substantial future capital, clinical trial complexities, and reliance on third-party intellectual property and services, which temper the overall positive sentiment.

Positives

• Net loss significantly decreased to $41.4 million for Q3 2025 from $66.3 million for Q3 2024, and to $152.1 million for the nine months ended September 30, 2025, from $197.7 million for the same period in 2024.
• Cash used in operating activities decreased to $121.6 million for the nine months ended September 30, 2025, from $163.6 million in the prior year period.
• The company expects its cash, cash equivalents, and investments of $277.1 million to fund operations into the second half of 2027, extending its cash runway.
• ALPHA3 pivotal Phase 2 trial for cema-cel is advancing with over 50 activated sites in the U.S. and Canada, and planned expansion to Australia and South Korea in early 2026.
• ALLO-316 for advanced/metastatic RCC received Regenerative Medicine Advanced Therapy (RMAT) designation, indicating potential for expedited development and review.
• ALLO-316 demonstrated a 31% confirmed overall response rate (ORR) in patients with high CD70 expression (TPS ≥50%) and 44% achieving at least a 30% tumor reduction, with four out of five confirmed responders maintaining responses, including one exceeding 12 months.
• Alignment has been reached with the FDA on the design of a registration trial for ALLO-316 in RCC.
• ALLO-329 for autoimmune diseases received three Fast Track Designations (FTD) from the FDA for systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc), potentially accelerating its development and review.
• The company's Dagger Platform Technology is being advanced for next-generation AlloCAR T product candidates, designed to minimize or eliminate the need for standard lymphodepletion.

Negatives

• The company continues to incur significant net losses, with a cumulative net loss of $2.0 billion as of September 30, 2025.
• A Grade 5 adverse event (hepatic failure from disseminated adenovirus infection) in the ALPHA3 trial's FCA arm led to its termination and the discontinuation of ALLO-647 from all trials, highlighting safety risks associated with lymphodepletion regimens.
• The company initiated a workforce reduction of approximately 28% of its employees in May 2025, incurring $3.3 million in cash-based severance payments and $1.3 million in equipment impairment charges.
• There is uncertainty regarding whether the standard fludarabine and cyclophosphamide (FC) lymphodepletion regimen alone will achieve sufficient lymphodepletion to support the efficacy of cema-cel in the ALPHA3 trial.
• The company is heavily reliant on partners like Cellectis and Servier for TALEN gene editing technology, and an ongoing arbitration between Cellectis and Servier could terminate the sublicense for key product candidates like cema-cel and ALLO-316.
• Heavy reliance on Foresight Diagnostics for the CLARITY MRD test in the ALPHA3 trial introduces risks related to assay performance, regulatory approval outside the U.S., and potential delays in patient enrollment.
• The company will need substantial additional financing to develop its products and implement operating plans, particularly for commercial production and registrational trials.

Risks

• Incurring substantial net losses in the future and needing significant additional financing to develop products and implement operating plans.
• Product candidates are based on novel technologies, making it difficult to predict development time, cost, and likelihood of regulatory approval.
• High dependence on the success of lead product candidates (cema-cel, ALLO-316, ALLO-329); failure would significantly harm the business.
• Product candidates may cause undesirable side effects (e.g., CRS, neurotoxicity, GvHD, IEC-HS, prolonged cytopenia, infections) that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• Clinical trials may fail to demonstrate safety and efficacy, leading to delays or denial of regulatory approval.
• Risks related to serious adverse events (SAEs) in the discontinued FCA arm of the ALPHA3 trial, including the Grade 5 SAE, could lead to regulatory actions, negative perceptions, and potential product liability claims.
• No CAR T therapy has been approved as a first-line consolidation strategy for LBCL, presenting significant regulatory, commercial, and operational risks.
• Substantial delays in clinical trials or inability to conduct trials on expected timelines due to various factors, including patient enrollment difficulties and regulatory requirements.
• Failure to successfully manufacture product candidates, operate the manufacturing facility (CF1), or obtain regulatory approval for its use.
• Reduced manufacturing operations may limit the ability to timely support development programs and future ramp-up could be costly and delayed.
• Significant competition from other biotechnology and pharmaceutical companies, including those developing in vivo cell-engineering technologies.
• Heavy reliance on key personnel; difficulty attracting and retaining highly qualified staff.
• Disruptions to operations of regulatory agencies (FDA, SEC) due to funding shortages or policy changes could hinder timely review and approval.
• Uncertainty regarding whether the use of fludarabine and cyclophosphamide (FC) without ALLO-647 will achieve sufficient lymphodepletion for ALPHA3 efficacy.
• Heavy reliance on Cellectis and Servier for access to TALEN gene editing technology, with an ongoing arbitration between them potentially impacting sublicenses.
• Heavy reliance on Foresight Diagnostics for access to their CLARITY MRD test for ALPHA3 patient identification, with risks related to assay performance, regulatory approval, and logistics.
• Dependence on intellectual property licensed from third parties; termination of any licenses could result in loss of significant rights.
• Third-party claims of intellectual property infringement (e.g., Factor Litigation against Cellectis) may prevent or delay product development and commercialization.
• The price of common stock has been and may continue to be volatile, leading to potential loss of investment.
• Failure to establish and maintain effective internal control over financial reporting could result in material misstatements and loss of investor confidence.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future, with research and development and general and administrative expenses anticipated to increase. It believes its current cash, cash equivalents, and investments will fund operations into the second half of 2027. The company intends to raise additional capital through equity securities, debt financings, or other sources to fully implement its business plan. If financing is not available, it may be required to delay product candidate development. The next key milestone is the futility analysis for the ALPHA3 trial, expected in the first half of 2026, with proof-of-concept data for ALLO-329 also anticipated in the first half of 2026. The company is actively exploring strategic opportunities, including potential partnerships, to advance the ALLO-316 program.

Management Comments

• We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases.
• We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.
• We now have over 50 activated trial sites in the United States and Canada for ALPHA3, with additional sites in Australia and South Korea progressing toward activation and expected to open in early 2026.
• The decision to select standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for ALPHA3 was made in conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee and following consultation with the U.S. Food and Drug Administration (FDA).
• We continue to believe this approach (diagnostic and treatment algorithm for IEC-HS) has proven effective by enabling early intervention and effective management, resulting in a safety profile consistent with standard lymphodepletion and active CAR T treatment.
• We believe we have reached alignment with the FDA on the design of a registration trial for adult patients with advanced or metastatic RCC for ALLO-316.
• We anticipate having proof-of-concept data by the first half of 2026 for ALLO-329, which we anticipate will include both biomarker and clinical data.
• We believe we currently hold sufficient inventory of cema-cel, ALLO-329, and ALLO-316 to meet our near-term clinical needs, including completing our current ALPHA3, RESOLUTION and TRAVERSE trials.
• We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses and general and administrative expenses will continue to increase.
• We expect that our cash, cash equivalents and investments will be sufficient to fund our operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).

Industry Context

The company operates in the highly competitive and rapidly innovating biopharmaceutical and immuno-oncology industries, specifically focusing on novel allogeneic CAR T cell therapies. This approach contrasts with established autologous CAR T therapies (e.g., Kymriah, Yescarta) and faces emerging competition from in vivo cell-engineering technologies. The regulatory landscape for these novel therapies is still developing, leading to complex and lengthy approval processes. The company's strategy to target minimal residual disease (MRD) in first-line consolidation for LBCL is an unproven setting for CAR T therapy, presenting unique regulatory and commercial challenges. The industry is also seeing increased investor interest in in vivo platforms, which could impact capital raising for ex vivo allogeneic approaches.

Comparison to Industry Standards

• The company's allogeneic CAR T approach is a novel technology, differing from existing autologous CAR T therapies like Kymriah and Yescarta, which are derived from an individual patient for that patient's use.
• No CAR T therapy has been approved as part of a first-line consolidation strategy for LBCL patients, making Allogene's ALPHA3 trial a pioneering effort in an unproven setting, which presents significant regulatory and commercial risks compared to established treatment paradigms.
• The company's Dagger Platform Technology aims to minimize or eliminate the need for standard lymphodepletion, potentially offering an advantage over current CAR T therapies that require intensive pre-conditioning regimens.
• The Grade 5 adverse event in the ALPHA3 FCA arm, attributed to ALLO-647, highlights safety challenges that can arise with lymphodepletion regimens, a common component in CAR T therapy, and underscores the need for careful management of immunosuppression compared to industry benchmarks.
• The company faces competition from major multinational pharmaceutical companies, established biotechnology companies, and smaller early-stage companies, many of which have greater financial and technical resources, including those developing in vivo cell-engineering technologies and bispecific antibodies for indications like multiple myeloma and LBCL.

Management Changes

Legal Proceedings

• An ongoing arbitration between Cellectis and Servier regarding the Servier-Cellectis Agreement, where Cellectis is seeking termination, which would automatically terminate the company's sublicense from Servier. An arbitral decision is expected on or before December 15, 2025.
• Factor Bioscience Inc. filed a complaint against Cellectis S.A. and its affiliate, alleging infringement of three U.S. patents related to gene-editing techniques (Factor Litigation). The company is not a party but relies on Cellectis's TALEN technology, and Factor may assert direct claims against the company.

Related Party Transactions

• A sublease agreement with Bellco Capital LLC for office space in Los Angeles, California, where the company's executive chairman, Arie Belldegrun, M.D., is a trustee of the controlling Belldegrun Family Trust. Rent expense was $0.1 million for the three months and $0.3 million for the nine months ended September 30, 2025.
• A consulting agreement with Bellco, where Bellco provides services performed by Dr. Belldegrun. Costs incurred were $0.2 million for the three months and $0.6 million for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity capital raises and continued stock price volatility due to clinical trial outcomes and market conditions.
• Employees experienced a workforce reduction of approximately 28% in May 2025, impacting morale and potentially leading to loss of institutional knowledge.
• Patients in clinical trials are directly impacted by changes in trial design (e.g., ALPHA3 lymphodepletion regimen), safety events (Grade 5 SAE), and the potential for delays in product development.
• Partners (e.g., Cellectis, Servier, Foresight Diagnostics) are critical to the company's development programs, and disputes or performance issues could impact the company's ability to advance its product candidates.
• Creditors and investors are affected by the company's ongoing net losses and its need for substantial additional financing, which could influence the terms of future debt or equity offerings.

Next Steps

• Conduct futility analysis comparing minimal residual disease (MRD) conversion in the ALPHA3 trial, expected in the first half of 2026.
• Provide guidance on the timing of additional ALPHA3 milestones following the futility analysis.
• Advance the ALLO-316 development program, including exploring strategic opportunities and potential partnerships for a registration trial.
• Obtain proof-of-concept data (biomarker and clinical) for the ALLO-329 RESOLUTION trial by the first half of 2026.
• Continue to explore opportunities to partner with collaborators on product candidates across the pipeline.
• Raise additional capital through equity securities, debt financings, or other sources to fund operations and product development.

Key Dates

Recommendation

Allogene Therapeutics demonstrates promising clinical progress with its lead CAR T programs, including RMAT and Fast Track designations, and has reduced its net losses and extended its cash runway. These are positive indicators for long-term potential. However, the company continues to incur substantial losses, faces significant clinical and regulatory risks (e.g., Grade 5 SAE, unproven 1L consolidation setting, reliance on third-party IP), and will require substantial additional capital. The ongoing legal proceedings and reliance on key partners also introduce uncertainty. Given the high-risk, high-reward nature of clinical-stage biotech, coupled with the need for future financing and the inherent volatility, a 'hold' recommendation is appropriate for investors who are already exposed to the stock and believe in the long-term vision, but new investors should exercise caution due to the significant risks.

Keywords

Allogene Therapeutics, CAR T cell therapy, Immuno-oncology, Autoimmune diseases, cema-cel, ALLO-316, ALLO-329, ALPHA3 trial, TRAVERSE trial, RESOLUTION trial, Large B-cell lymphoma, Renal cell carcinoma, Systemic lupus erythematosus, Idiopathic inflammatory myopathies, Systemic sclerosis, Gene editing, TALEN technology, Dagger Platform Technology, MRD assay, Clinical trials, Biotechnology, Pharmaceuticals, SEC filing, 10-Q